203 related articles for article (PubMed ID: 23554933)
1. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials.
Andrews KA; Modat M; Macdonald KE; Yeatman T; Cardoso MJ; Leung KK; Barnes J; Villemagne VL; Rowe CC; Fox NC; Ourselin S; Schott JM;
PLoS One; 2013; 8(3):e58816. PubMed ID: 23554933
[TBL] [Abstract][Full Text] [Related]
2. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.
Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
JAMA Neurol; 2013 Aug; 70(8):1030-8. PubMed ID: 23797806
[TBL] [Abstract][Full Text] [Related]
3. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.
Petersen RC; Wiste HJ; Weigand SD; Rocca WA; Roberts RO; Mielke MM; Lowe VJ; Knopman DS; Pankratz VS; Machulda MM; Geda YE; Jack CR
JAMA Neurol; 2016 Jan; 73(1):85-92. PubMed ID: 26595683
[TBL] [Abstract][Full Text] [Related]
4. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T;
Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
[TBL] [Abstract][Full Text] [Related]
6. Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis.
Andrews KA; Frost C; Modat M; Cardoso MJ; ; Rowe CC; Villemagne V; Fox NC; Ourselin S; Schott JM
Neurobiol Aging; 2016 Mar; 39():99-107. PubMed ID: 26923406
[TBL] [Abstract][Full Text] [Related]
7. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
8. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
10. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.
Bourgeat P; Chételat G; Villemagne VL; Fripp J; Raniga P; Pike K; Acosta O; Szoeke C; Ourselin S; Ames D; Ellis KA; Martins RN; Masters CL; Rowe CC; Salvado O;
Neurology; 2010 Jan; 74(2):121-7. PubMed ID: 20065247
[TBL] [Abstract][Full Text] [Related]
11. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
[TBL] [Abstract][Full Text] [Related]
12. Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan.
Luo J; Agboola F; Grant E; Morris JC; Masters CL; Albert MS; Johnson SC; McDade EM; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Wang G; Li Y; Gordon B; Cruchaga C; Day GS; Levin J; Vöglein J; Ikeuchi T; Suzuki K; Allegri RF; Xiong C;
Brain; 2022 Dec; 145(12):4459-4473. PubMed ID: 35925685
[TBL] [Abstract][Full Text] [Related]
13. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
14. Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB-PET Threshold.
Ismail R; Parbo P; Hansen KV; Schaldemose JL; Dalby RB; Tietze A; Kjeldsen PL; la Cour SH; Qvist P; Gottrup H; Eskildsen SF; Brooks DJ
J Neuroimaging; 2019 Jul; 29(4):499-505. PubMed ID: 31074062
[TBL] [Abstract][Full Text] [Related]
15. Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity.
Park JE; Yun J; Kim SJ; Shim WH; Oh JS; Oh M; Roh JH; Seo SW; Oh SJ; Kim JS
PLoS One; 2019; 14(12):e0226265. PubMed ID: 31834916
[TBL] [Abstract][Full Text] [Related]
16. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
17. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
[TBL] [Abstract][Full Text] [Related]
18. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
19. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
[TBL] [Abstract][Full Text] [Related]
20. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.
Drzezga A; Grimmer T; Henriksen G; Mühlau M; Perneczky R; Miederer I; Praus C; Sorg C; Wohlschläger A; Riemenschneider M; Wester HJ; Foerstl H; Schwaiger M; Kurz A
Neurology; 2009 Apr; 72(17):1487-94. PubMed ID: 19339712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
